The Weekly Bioanalysis - An Official Podcast of KCAS

CEO of KCAS Bio, John Bucksath, joins Dom and John for a special 75th episode of “The Weekly Bioanalysis” podcast, and he is absolutely delighted to use the special episode to talk about the recent rebrand of KCAS to KCAS Bio! Mr Bucksath and our hosts discuss the reason the rebrand came about, the process our organization took, and some of the initial reactions our team have experienced from our...

During this episode of “The Weekly Bioanalysis”, Dom and John talk about addressing the needs of rare diseases - some challenges and industry trends they’ve watched take place, and they are joined by guest, Lindsay Rutherford, who has her own personal experience with rare disease and how it can impact lives. As a bioanalytical provider, KCAS Bio of course has a unique take on this topic as well, a...

To kick off the first episode of “The Weekly Bioanalysis” in 2024, Dom and John unveil some fun new things happening at KCAS, by talking about the parallel evolution of the bioanalytical industry and KCAS. Our hosts go way back – almost to “square one” (discussing “What is bioanalysis?” and “How has bioanalysis changed over the years?”. They take a nice little dip back into history and then and th...

For the final episode of “The Weekly Bioanalysis” in 2023, Dom and John invited KCAS’s scientific advisory team to join them, as we thought that as we are coming to the end of the year, it might be a good opportunity to introduce a few members of the scientific advisory team who may be involved in some greater capacity with the podcast going forward, as the organization grows and expands. Then our...

Dom and John have been doing this for a long time (for over 70 episodes now, to be exact), but they felt it might be a good idea to jump back to the very beginning and discuss the overarching concept of the Drug Development process and where it is that Bioanalysis fits in. This is somewhat of a response to a recent listener request, but we also feel its important every once in a while to refocus a...

It is that time of year once again... the Fall Conference Season! Every industry has its own set of important trade shows and meetings, but for the Pharma, biotech and bioanalytical industries, these conferences are an opportunity for the planet's leading experts to get together and share the newest ways to heal the world. With October almost upon us, Dom and John discuss the upcoming confere...

Starting off with a description of Antibody Drug Conjugates (or ADCs, for short), Dom and John dive into this field of the industry and discuss the ways these services have changed over time and even how they've changed recently. They review the role of ADCs in meeting some of the unmet medical needs in oncology and the way they're changing the effectiveness of some of the most modern dr...

Special guest Carrie Vyhlidal, PhD of KCAS joins John and Dom in the 68th episode of "The Weekly Bioanalysis" to discuss the ways molecular cell & gene therapy services has evolved and why their role will likely become more and more important to the world of bioanalytical drug development in the future. They discuss everything from the history of Cell & Gene Therapies and the top...

In the world of bioanalysis, pharmacokinetics is a key step in the process of measuring and identifying elements of the drug. It is a baseline for sample analysis, and in episode 67 of "The Weekly Bioanalysis", Dom and John discuss the history and evolution drug and pharmacokinetic modalities and the impact on regulations. "The Weekly Bioanalysis" is a podcast dedicated to disc...

Special guests Dawn Duffield, PhD of KCAS and Barry Jones, PhD of Crinetics join John and Dom in the 66th episode of "The Weekly Bioanalysis" to discuss the ways Hybrid LC-MS/MS has advanced in recent years and how the technology has gone from "new" and somewhat obscure to much more mainstream as a leading option for program success within the pharmaceutical and biopharmaceutic...

Dom and John discuss the role early non-clinical bio analysis plays in your project, why it is important, how it has changed over the years, and what might be next for this growing part of the industry. "The Weekly Bioanalysis" is a podcast dedicated to discussing Bioanalytical news, tools and services related to the Pharmaceutical, Biopharmaceutical and Biomarker industries. Every month...

In what is becoming an annual tradition here on “The Weekly Bioanalysis” podcast, Dom and John take a bit of time to take a look back at 2022’s Fierce 15 (the annual selected list of impressively performing companies across the biotech world, highlighting a broad range of teams, leaders and science, as selected by the Fierce Biotech group). In addition to this, the guys discuss the list of drugs t...

It has been an extremely transformative year for KCAS in 2022. As we approach the beginning of 2023, Dom and John take a moment during episode #63 to look back at all the changes and evolutionary growth that has transpired around the organization (and around the world, as we now have multiple European footprints as well as US locations). They go into detail about the opportunities these changes ha...

Special guests John Bucksath, CEO of KCAS in Olathe, KS and Marc Essodaigui, General Manager of Active Biomarkers in Lyon, France, join Dom and John this week as they introduce our listeners to Active Biomarkers – the most recent acquisition of KCAS in the European space. The gentlemen discuss a brief history of Active Biomarkers, the path to their acquisition by KCAS, and what it now means – for...

Every year, beginning in late August, with the summer over and everyone settling back into a normal routine, the entire industry begins preparing itself for the conference and trade show season. These events serve as a source for new business in some cases, of course, but they also serve as an opportunity for like-minded scientists and industry leaders to discuss their findings and discoveries ove...

Clinical Sample Kitting and Sample Storage have played vital roles in the pharmaceutical and Biopharmaceutical industry for decades, but KCAS began offering the services in the early 1990s in response to shortcomings observed in the collection techniques in trials where we were providing bioanalytical support. During episode #60 of "The Weekly Bioanalysis" podcast, John Pirro and John Pe...

For the 59th episode of KCAS's podcast, Dom and John are excited to welcome a special guest to the show! John Pirro has been a team member for years now at KCAS, but he joins “The Weekly Bioanalysis” this episode to showcase the changes involved in his new SSA (Senior Scientific Advisor) role, and the team talks a bit about what this means for KCAS's clients’ projects – especially our Li...

In this 58th episode of "The Weekly Bioanalysis" podcast, Dom and John wrap up their 2-part series on the Evolution of Bioanalysis, as they dive into the history of their bioanalysis careers by reviewing Drug Design and Development, and how that has effected the things CROs like KCAS do today. They discuss where the pharmaceutical and biopharmaceutical industry has been, and work their f...

During the 57th episode of "The Weekly Bioanalysis" podcast, Dom and John have a chance to dive into their history of their bioanalysis careers by reviewing the evolution of Drug Design and Development, and how that has effected the things CROs like KCAS do today. They discuss where the pharmaceutical and biopharmaceutical industry has been, and work their way through to roughly 2010 or...

For the 56th episode of “The Weekly Bioanalysis” podcast, the Senior Director of Cell & Gene Therapy Services at KCAS, Jeff Hester, PhD, joins Dom and John to discuss the growing field of Cell & Gene Therapy. Cell and gene therapies (CGTs) are types of treatment that use cellular or genetic material with the goal of treating a disease or a disorder. Often it can be a combination of cell an...

Even while many in the industry have pulled back on growth and expansion efforts after COVID's years-long effect on business and supply lines worldwide, KCAS is in a unique position - as a result of many years of sound decision making and customer relationship building - to expand its operations into an all-new facility full of state-of-the-art equipment and technology throughout. During this...

Earlier this month, KCAS announced the acquisition of FlowMetric, LLC, a leading provider of flow cytometry and cellular assay R&D services to biotech, pharmaceutical and cell/gene therapy industries. With the KCAS family growing, Dom and John took the opportunity to invite Renold Capocasale, the Vice Chair and Founder of FlowMetric, to join the podcast for episode #54 to discuss what the rece...

For the first episode of “the Weekly Bioanalysis” in 2022 (also the first episode of our “second season” of the podcast), Dom and John speak to a topic that is near and dear to their hearts: The role Bioanalysis plays in your projects. KCAS offers so many services, but as technologies and discoveries within the industry advance, it is important to understand the ways each type of service can help...

As most Americans were wrapping up their Thanksgiving and Black Friday rituals just a few weeks ago, many felt the corner had finally been turned on COVID and we would all be able to start finally getting back to normal… instead, within days, we were all greeted with news about a new mutation of the COVID-19 virus that had been detected by scientists in Johannesburg. With so many concerns lingerin...

Although the world now has a number of vaccines in place and available to serve as a preventative and/or impact-reduction method for COVID, there are a number of reasons that it is also important for the Pharma and Biopharma industries to continue developing other treatment and medicines to for those who become infected - with or without having taken the vaccine. Lucky for all of us, there are a f...